The Global Onychomycosis Market is Predict to reach $4.5 Billion by 2028, at a CAGR of 4.8%

Onychomycosis Market Growth, Trends and Report Highlights

According to a new report, published by KBV research, The Global Onychomycosis Market size is expected to reach $4.5 billion by 2028, rising at a market growth of 4.8% CAGR during the forecast period.

The White Superficial segment is showcasing a CAGR of 5% during (2022 - 2028). This is because this particular nail fungal infection is less common. Only toenails are impacted, and the fungus colonizes the surface of the nail plate, leaving behind numerous white, friable nail plate patches. This infection always requires a comprehensive approach to treatment. This infection is brought on by T. mentagrophytes. It is much rarer than other forms of onychomycosis.

The Topical segment acquired maximum revenue share in the Global Onychomycosis Market by Treatment in 2021 thereby, achieving a market value of $2.7 billion by 2028. The growth of the segment is owed to the lower occurrence of the negative effects of topical therapies. Additionally, new topical formulations that respond more quickly than currently existing topical medicines are being studied. For instance, JUBLIA, a topical formulation of efinaconazole developed for treating onychomycosis, was approved by the American Podiatric Medical Association (APMA) in December 2021.

The North America market dominated the Global Onychomycosis Market by Region in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $1.8 billion by 2028. The Europe market is exhibiting a CAGR of 4.6% during (2022 - 2028). Additionally, The Asia Pacific market would showcase a CAGR of 5.6% during (2022 - 2028).

Full Report: https://www.kbvresearch.com/onychomycosis-market/

The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the globe with country wise analysis in each discussed region. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of Pfizer, Inc., Teva Pharmaceuticals Industries Ltd., Abbott Laboratories, Bausch Health Companies, Inc., Bayer AG, Cipla Limited, Merck & Co., Inc., Novartis AG, Sun Pharmaceutical Industries Ltd., and GlaxoSmithKline PLC.

Global Onychomycosis Market Segmentation

By Type

• Distal Subungual
• Proximal Subungual
• White Superficial
• Others

By Treatment

• Topical
• Oral
• Others

By Geography

• North America
  • US
  • Canada
  • Mexico
  • Rest of North America
• Europe
  • Germany
  • UK
  • France
  • Russia
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Singapore
  • Australia
  • Rest of Asia Pacific
• LAMEA
  • Brazil
  • Argentina
  • UAE
  • Saudi Arabia
  • South Africa
  • Nigeria
  • Rest of LAMEA

Companies Profiled

• Pfizer, Inc.
• Teva Pharmaceuticals Industries Ltd.
• Abbott Laboratories
• Bausch Health Companies, Inc.
• Bayer AG
• Cipla Limited
• Merck & Co., Inc.
• Novartis AG
• Sun Pharmaceutical Industries Ltd.
• GlaxoSmithKline PLC

Unique Offerings from KBV Research

• Exhaustive coverage
• The highest number of market tables and figures
• Subscription-based model available
• Guaranteed best price
• Assured post sales research support with 10% customization free

Related Reports:

North America Onychomycosis Market Future Scope & Opportunities 2022-2028

Europe Onychomycosis Market Size & Growth Forecast 2022-2028

Asia Pacific Onychomycosis Market Size, Share & Industry Outlook to 2028

LAMEA Onychomycosis Market Growth, Trends & Forecasts 2022-2028